Development of electrochemiluminescent serology assays to measure the humoral response to antigens of respiratory syncytial virus

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Maifeld, Sarah V ^a   Ro, Bodrey ^a,d   Mok, Hoyin ^a   Chu, Marla ^a   Yu, Li ^a   Yamagata, Ryan ^a   Leonardson, Tansy ^a   Chio, Vera ^a   Parhy, Bandita ^a,b   Park, Samuel ^a,d   Carlson, Marcia ^a   Machhi, Shushil ^a   Ulbrandt, Nancy ^b   Falsey, Ann R ^c   Walsh, Edward E ^c   Kathy Wang, C ^a   Esser, Mark T ^a   Zuo, Fengrong ^a,e  

^a MEDIMMUNE   (United States)

^b Department of Infectious Disease and Vaccines ^*  (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d GENENTECH INC   (United States)

^e Medivation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CELL ASSAY; CELL BASED MICRONEUTRALIZATION ASSAY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GOLD STANDARD; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; INTERMETHOD COMPARISON; NONHUMAN; POPULATION RESEARCH; PROCESS DEVELOPMENT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SENSITIVITY AND SPECIFICITY; BLOOD; EVALUATION STUDY; IMMUNOLOGY; INFANT; LUMINESCENCE; PRESCHOOL CHILD; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERODIAGNOSIS; SEROLOGY;

ATTACHMENT PROTEIN G; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, HUMORAL; INFANT; LUMINESCENT MEASUREMENTS; NEUTRALIZATION TESTS; NUCLEOCAPSID PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEROLOGIC TESTS; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS;

EID: 84963537566     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153019     Document Type: Article

References (47)

1. Falsey AR, McElhaney JE, Beran J, Van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014; 209: 1873-1881. doi: 10.1093/infdis/jit839 PMID: 24482398
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhir SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010; 375: 1545-1555. doi: 10.1016/S0140-6736(10)60206-1 PMID: 20399493
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352: 1749-1759. PMID: 15858184
4. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
5. Anderson L, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013; 31: B209-B215. doi: 10.1016/j. vaccine.2012.11.106 PMID: 23598484
6. Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, et al. Translational sciences approach to RSV vaccine development. Expert Rev Vaccines 2013; 12: 1047-1060. doi: 10.1586/14760584.2013. 824706 PMID: 24053398
7. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: Comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002; 40: 817-820. PMID: 11880399
8. Connors MP, Collins PL, Firestone LY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol. 1991; 65: 1634-1637. PMID: 1995956
9. Rudraraju R, Jones GB, Sealy R, Surman S, Hurwitz JL. Respiratory syncytial virus: Current progress in vaccine development. Viruses 2013; 5: 577-594. doi: 10.3390/v5020577 PMID: 23385470
10. Guvenel AK, Chiu C, Openshaw PJM. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines 2014; 13: 333-344. doi: 10.1586/14760584.2014.878653 PMID: 24405366
11. Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol. 2013; 25: 160-171. doi: 10.1016/j.smim.2013.04.011 PMID: 23778071
12. Buraphacheep W, Britt WJ, Sullender WM. Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens. J Clin Microbiol. 1997; 35: 354-357. PMID: 9003595
13. Sastre P, Cusi MG, Manoha C, Schildgen O, Rui T, Vela C, et al. Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: Children and elderly. J Virol Methods 2010; 168: 170-176. doi: 10.1016/j.jviromet.2010.05.011 PMID: 20488207
14. Kumari S, Crim RL, Kulkarni A, Audet SA, Mdluli T, Murata H, et al. Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein. Clin Vaccine Immunol. 2014; 21: 383-390. doi: 10.1128/CVI.00594-13 PMID: 24403526
15. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection. J Infect Dis. 1998; 177: 463-464. PMID: 9466538
16. Langedijk JP, Brandenburg AH, Middel WG, Osterhaus A, Meloen RH, Van Oirschot JT. A subtype-specific peptide-based enzyme immunoassay for detection of antibodies to the G protein of human respiratory syncytial virus is more sensitive than routine serological tests. J Clin Microbiol. 1997; 35: 1656-1660. PMID: 9196168
17. Johnson PR, Collins PL. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol. 1988; 69: 2623-2628. PMID: 3171553
18. Johnson PR, Collins PL. The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: Sequence conservation and divergence within RSV genomic RNA. J Gen Virol. 1989; 70: 1539-1547. PMID: 2525176
19. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol. 1997; 78: 2411-2418. PMID: 9349459
20. Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: Extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA. 1987; 84: 5625-5629. PMID: 2441388
21. Anderson LJ, Hierholzer JC, Tsou C, Hendry MR, Fernie BF, Stone Y, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis. 1985; 151: 626-633. PMID: 2579169
22. Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol. 1985; 66: 2111-2124. PMID: 2413163
23. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev. 2000; 13: 1-15. PMID: 10627488
24. Saah AJ, Hoover DR. "Sensitivity" and "Specificity" reconsidered: The meaning of these terms in analytical and diagnostic settings. Ann Intern Med. 1997; 126: 91-97. PMID: 8992938
25. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol. 2004; 78: 11198-11207. PMID: 15452239
26. Sebaugh JL, McCray PD. Defining the linear portion of a sigmoid-shaped curve: Bend points. Pharmaceut. Statist. 2003; 2: 167-174.
27. Jiang J. Linear and Generalized Linear Mixed Models and Their Application. New York: Springer Science+ Business Media; 2007.
28. Deaver DR. A new, non-isotopic detection system for immunoassays. Nature 1995; 377:758-760. PMID: 7477271
29. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. 2007; J Mol Biol 386: 652-665.
30. Richardson LS, Yolken RH, Belshe RB, Camargo E, Kim HW, Chanock RM. Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect Immun. 1978; 20: 660-664. PMID: 352952
31. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008; 198: 1317-1326. doi: 10.1086/592168 PMID: 18855558
32. Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31: 524-532. doi: 10.1016/j.vaccine.2012.11.009 PMID: 23153449
33. Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One 2013; 8: 1-10.
34. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory-syncytial-virus infections, re-infections and immunity: A prospective, longitudinal study in young children. 1979; 300: 530-534.
35. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001; 33:792-796. PMID: 11512084
36. Brandenburg AH, Groen J, v. Steensel-Moll HA, Claas ECJ, Rothbarth PH, Neijens J, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: Limited serological response upon infection. J Med Virol; 1997; 52: 97-104. PMID: 9131465
37. Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis. 2014; 210: 1582-1589. doi: 10.1093/infdis/jiu316 PMID: 24903663
38. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The level and duration of RSVspecific maternal IgG in infants in Kilifi Kenya. PLoS One 4: E8088. doi: 10.1371/journal.pone.0008088 PMID: 19956576
39. Burton D. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002; 2: 706-713. PMID: 12209139
40. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: The two extremes of a wide spectrum. Nat Rev Immunol. 2006; 6: 213-243.
41. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004; 190: 373-378. PMID: 15216475
42. Walsh EE, Peterson DR, Kalkanoglu AE, Lee F E-H, Falsey AR. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis. 2013; 207: 1424-1432. doi: 10.1093/infdis/jit038 PMID: 23382572
43. Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis. 1988; 157: 640-647. PMID: 3346563
44. Muelenaer PM, Henderson FW, Hemming VG, Walsh EE, Anderson LJ, Prince GA, et al. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis. 1991; 164: 15-21. PMID: 2056202
45. Cane PA, Thomas HW, Simpson AF, Evans JE, Hart CA, Pringle CR. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol. 1996; 48: 253-261. PMID: 8801286
46. Murata Y, Lightfoote PM, Biear JN, Falsey AR, Walsh EE. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine 2010; 28: 6242-6246. doi: 10.1016/j.vaccine.2010.07.011 PMID: 20655403
47. Englund JA, Piedra PA, Jewell A, Kirti P, Baxter BB, Whimbey E. Rapid Diagnosis of Respiratory Syncytial Virus Infections in Immunocompromised Adults. J Clin Microbiol 1996; 34: 1649-1653. PMID: 8784563